Children’s Hospitals Are Increasingly Using the NeuroCap™ to Monitor Pediatric Patients
Children's Hospitals Are Increasingly Using the NeuroCap™ to Monitor Pediatric Patients
Brain Scientific Continues to See Rapid Adoption of NeuroCap in Key Markets: Ones That Make a Difference, Like Ensuring Children Get Time-Sensitive Care for Threatening Conditions
Brain Scientific (OTCQB:BRSF), a Florida-based applied science technology company, announced today that they are seeing an uptick in orders of their NeuroCaps for pediatric patients.
“We are excited by the international enthusiasm around the use of the NeuroCap in pediatric settings in major markets, such as the United States, Israel, France, and the United Kingdom,” said Daniel Cloutier, CRO of Brain Scientific. “More and more, we are seeing the use of NeuroCaps on pediatric patients by nursing staff rather than trained EEG technologists. They use them in lieu of traditional EEG monitoring during the overnight hours when an EEG technologist is unavailable for set-ups.”
When children are brought to the hospital for overnight emergencies requiring an EEG exam, the NeuroCap allows nursing staff to begin testing immediately, rather than waiting hours for trained EEG technologists to arrive. The time savings offered by NeuroCap can make a critical difference in patient outcomes.
“Beyond the wearable technology hype lies substantial value to our communities and healthcare system, like helping catch life-threatening conditions in the most vulnerable populations: our children and the elderly,” said Hassan Kotob, CEO of Brain Scientific. “That’s why we do this. That’s why we are dedicated to bringing forth wearable technology that moves the world forward in a positive way. Our NeuroCap is just the beginning for Brain Scientific, but it is already making a critical difference in our healthcare systems in the U.S. and abroad.”
About Brain Scientific
Brain Scientific Inc. (brainscientific.com) is an applied sciences technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of medical and OEM devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap™ and NeuroEEG™ are smart neurological diagnostic devices that simplify administration, shorten scan time and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of OEM devices. To learn more about Brain Scientific's corporate strategy, products or investor relations, please visit brainscientific.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company's future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company's inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company's inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company's raw materials; and the failure to implement the company's business plans or strategies. Some of these and other factors are identified and described in more detail in the company's filings with the SEC. The company does not undertake to update these forward-looking statements.
Leave a Comment